Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~To be eligible to participate in this study, all of the following criteria must be met:~* Subject is informed and given approved written Informed Consent Form (ICF).~* Subject is considered reliable and capable of adhering to the protocol.~* Subject must have a diagnosis of adult-onset moderate-to-severe RA of at least 6 months' duration as defined by ACR/EULAR 2010 classification criteria.~* Subject must have:~  * ≥6 tender joints (out of 68)~ * ≥6 swollen joints (out of 66)~ * CRP≥10.0mg/L .~* Subject must have had inadequate response to at least 1 synthetic DMARD.~* Subject is at least 18 years and less than 70 years of age at Visit 1 (Screening).~* Female subjects must either be:~  * postmenopausal~ * permanently sterilized or,~ * if of childbearing potential, must be willing to use at least 2 effective methods of contraception,~* Male subjects with partners of childbearing potential must be willing to use a condom when sexually active, during the study and for 5 months after last administration of study drug.~Exclusion Criteria~Subjects are not permitted to enroll in the study if any of the following criteria is met:~* Subject has previously participated in this study or has previously been assigned to treatment in a study of the investigational medicinal product (IMP) under investigation in this study (UCB4940 and/or CZP).~* Subject has a history or active systemic/respiratory infection due to fungal, parasitic, or mycotic pathogens.~* Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB infection are excluded.~* Subject is at high risk of infection.~* Subject has an active infection or has had a serious infection within 12 weeks prior to the first dose of study drug at Week 0.~* Subject has renal or liver impairment.~* Subject has a current or past history of gastrointestinal ulceration.~* Subject has active neoplastic disease or history of neoplastic disease.~* Subject has a concomitant diagnosis of any other inflammatory condition.~* Subject has a secondary, non-inflammatory condition or a known diagnosis of fibromyalgia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CZP / CZP + PBO / CZP (Type: PLACEBO_COMPARATOR): Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+Placebo from Week 8 to Week 18
- CZP / CZP + UCB4940 / CZP (Type: EXPERIMENTAL): Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+ UCB4940 from Week 8 until Week 18
- CZP / CZP/ CZP (Type: OTHER): Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete